why isn't dpp-4 inhibitors used as first line treatment?

Sitagliptin, in combination with Sulfonylureas and Insulin, have an increased risk for low blood sugar. DPP-4s for Type 2 Diabetes are rarely used as the first line medication. Patients begin with a healthy diet, activity program, and metformin is often the first drug that is prescribed if the patient can take it.

Full Answer

Is DPP-4 inhibition a first-line treatment for type 2 diabetes?

DPP-4 inhibition is safe and well tolerated, the risk of hypoglycaemia is minimal, and DPP-4 inhibition is body-weight neutral. DPP-4 inhibition is suggested to be a first-line treatment of type-2 diabetes, particularly in its early stages in combination with metformin.

How do DPP-4 inhibitors work?

Dipeptidyl peptidase-4 (DPP-4) inhibitors are oral diabetes medications that inhibit the enzyme DPP-4, a ubiquitous enzyme that is expressed on the surface of most cell types and deactivates a variety of other bioactive peptides, including glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1).

When should DPP-4 inhibitors be stopped when taking GLP-1 receptor agonists?

A treatment with DPP-4 inhibitors should be stopped when GLP-1 receptor agonists are used. DPP-4 inhibitors can be used as monotherapy when metformin is contraindicated or not tolerated.

When should metformin and DPP-4 inhibitors be stopped?

A treatment with DPP-4 inhibitors should be stopped when GLP-1 receptor agonists are used. DPP-4 inhibitors can be used as monotherapy when metformin is contraindicated or not tolerated. Some studies have shown value of initial metformin-DPP-4 inhibitor combination therapy in special populations.

Why is there no DPP-4 with GLP-1?

Dipeptidyl peptidase-4 (DPP-4) inhibitors block the breakdown of GLP-1 and GIP to increase levels of the active hormones. In clinical trials, DPP-4 inhibitors have a modest impact on glycemic control. They are generally well-tolerated, weight neutral and do not increase the risk of hypoglycemia.

When do you not use DPP-4 inhibitors?

Patients should not stop taking their DPP-4 inhibitor medicine, but should contact their health care professional right away if they experience severe and persistent joint pain. Health care professionals should consider DPP-4 inhibitors as a possible cause of severe joint pain and discontinue the drug if appropriate.

Which is better DPP-4 or SGLT2?

SGLT2 inhibitors reduce HbA1c and fasting plasma glucose significantly more than DPP4 inhibitors without causing more hypoglycemic events among patients with type 2 diabetes.

Are DPP-4 inhibitors safe?

No class of diabetes drug agents has now been as thoroughly evaluated as the DPP4 inhibitors. Overall, they are safe without any increase in cardiovascular death, myocardial infarction, or stroke.

Can you use DPP-4 and GLP-1 together?

Concomitant use of once-weekly GLP-1 RAs and DPP-4 inhibitors provides only modest improvement in glycemic control with minimal weight loss benefits, which is similar to monotherapy with either agent. The combination is unlikely to provide synergistic effects and is not cost effective.

What are side effects of DPP-4 inhibitors?

Adverse effects of DPP-4 inhibitors include:gastrointestinal problems – including nausea, diarrhoea and stomach pain.flu-like symptoms – headache, runny nose, sore throat.skin reactions – painful skin followed by a red or purple rash.

Can you use DPP-4 with SGLT2?

Conclusion: Combination therapy with SGLT2i and DPP4i is both efficacious and safe. In particular, a marked additional glucose-lowering effect is evident when SGLT2i is combined with or added to DPP4i, and not vice versa.

Can you combine SGLT2 and GLP 1?

Conclusion: The combination of a GLP-1 agonist and an SGLT2-inhibitor has additive effects on lowering HbA1c and systolic blood pressure, body weight and cardiac risk and has the potential to synergistically reduce cardiovascular events and decelerate renal decompensation.

Is Januvia SGLT2 inhibitor?

Merck sells the DPP-4 inhibitor sitagliptin (Januvia). Merck also sells a combination DPP-4/SGLT2 inhibitor, sitagliptin/ertugliflozin (Steglujan).

Why do DPP-4 inhibitors not cause hypoglycemia?

DPP-4 inhibitors augment insulin secretion in a glucose-dependent manner, thus preventing hypoglycemia when used as monotherapy or in combination with antidiabetic agents which are known not to increase rates of hypoglycemia [Nauck et al. 2009].

Can you use DPP-4 in heart failure?

Clinical Trials on DPP4 Inhibitors and Heart Failure Therefore, current results do not support adverse effect on heart failure is a class effect of DPP4 inhibitor. However, DPP4 inhibition therapy may also do not possess beneficial cardiovascular effect.

Does DPP-4 cause hypoglycemia?

It has also been shown to slow gastric emptying [3] and inhibit inappropriate post-meal glucagon release (table 1) [1,4]. GLP-1-based therapies, including the DPP-4 inhibitors, do not usually cause hypoglycemia unless combined with therapies that can cause hypoglycemia [5].

What is the name of the first DPP-4 inhibitor?

Dipeptidyl Peptidase-4 Inhibitors. Sitagliptin : The first DPP-4 inhibitor to enter the U.S. market, Sitagliptin (Januvia), was approved in October 2006 as adjunctive therapy to diet and exercise in the treatment of type 2 diabetes. 13 It is a once-daily, highly selective, potent inhibitor of DPP-4 enzymes. Sitagliptin is eliminated primarily by the ...

What is the DPP-4 inhibitor?

DPP-4 inhibitors offer improved glycemic control in the management of type 2 diabetes, both alone and in combination with other antihyperglycemic agents, by reducing HbA 1C and improving beta-cell function . Agents such as sitagliptin and saxagliptin are available for first-line or adjunctive therapy.

What enzyme degrades GLP-1?

Circulating GIP and GLP-1 are rapidly degraded by the enzyme dipeptidyl peptidase-4 (DPP-4) ...

What are the two classes of medications that target the incretin system?

The two classes of medications currently available to target the incretin system are incretin mimetics/enhancers and DPP-4 inhibitors . Incretin mimetics resemble the biologic GLP-1 and are associated with transient nausea and GI discomfort.

What is the incretin effect?

6 The “incretin effect” can be defined by the greater insulin response to an oral glucose load than that experienced with an IV glucose challenge. 4,6,8 There are two incretin hormones, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). GIP, derived from purified porcine intestinal substance, was identified first and determined to have minimal effects on gastric acid secretion and a significant impact on insulin response in humans. GIP is produced from the duodenal and jejunal enteroendocrine K cells of the small bowel. GLP-1, synthesized from the enteroendocrine L cells of the distal ileum and colon, resulted from the cloning of complementary DNAs (cDNAs) and genes that encoded proglucagon. GLP-1 exists as GLP-1 (7-37) and GLP-1 (7-36), with GLP-1 (7-36) being more prevalent after food intake. 8 Both hormones, GIP and GLP-1, are secreted within minutes of the presence of food; however, GLP-1 is critical for glucose control. 8

How is sitagliptin eliminated?

Sitagliptin is eliminated primarily by the kidneys, with approximately 79% of the drug unchanged in patients with normal renal function. 14 The dose must be adjusted in patients with both moderate and severe renal impairment ( TABLE 2 ).

What is the place in therapy?

The American Association of Clinical Endocrinologists (AACE) and American College of Endocrinology (ACE) developed an algorithm to assist providers in managing type 2 diabetes.

What is DPP-4 inhibitor?

By Editor. Dipeptidyl peptidase-4 (DPP-4) inhibitors are a relatively new class of oral diabetes drugs. Also known as gliptins, they are usually prescribed for people with type 2 diabetes who have not responded well to drugs such as metformin and sulphonylureas. DPP-4 inhibitors may help with weight loss as well as decreasing blood glucose levels, ...

What is DPP-4 used for?

DPP-4 inhibitors may be used as a second or third line medication for people with type 2 diabetes after prescribing metformin and sulphonylureas, and as an alternative to thiazolidinedione medication.

How does incretin help the body?

Incretins help stimulate the production of insulin when it is needed (e.g. after eating) and reduce the production of glucagon by the liver when it is not needed (e.g. during digestion). They also slow down digestion and decrease appetite.

What are the side effects of DPP-4?

Adverse effects of DPP-4 inhibitors include: gastrointestinal problems – including nausea, diarrhoea and stomach pain. flu-like symptoms – headache, runny nose, sore throat. skin reactions – painful skin followed by a red or purple rash. If you have a reaction which causes difficulty breathing or a severe skin reaction, call for medical help.

Does DPP-4 cause nausea?

DPP-4 inhibitors have been linked with an increased risk of pancreatitis If you experience a severe pain in your upper abdomen which may be accompanied with nausea and/ or vomiting, call for medical help.

What enzyme inhibits insulin secretion?

Inhibits dipeptidyl peptidase IV (DPP-IV) enzyme , which prolongs the action of the incretin hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). These incretin hormones increase insulin secretion and decrease glucagon secretion, which also decreases hepatic glucose production.

Can DPP IV be taken with food?

Can be taken with or without food. DPP-IV inhibitors are FDA approved for use as monotherapy in type 2 diabetes (T2DM). DPP-IV inhibitors can also be added to patients already on metformin, sulfonylureas, thiazolidinediones, or insulin. If adding DPP-IV inhibitors to sulfonylurea /insulin therapy, consider decreasing the sulfonylurea/insulin dose, ...

How does DPP-4 work?

DPP-4 inhibitors work by using the DPP-4 enzyme to inhibit the breakdown of GLP-1, a naturally occurring incretin hormone produced by the body, according to the American Diabetes Association . GLP-1 lowers blood sugar levels. DPP-4 inhibitors allow GLP-1 to remain active in the body longer and to lower blood sugar levels only when they are too high.

What are the side effects of DPP-4?

Side effects include: upper respiratory tract infection (sitagliptin and saxagliptin) nasopharyngitis (sitagliptin) headache (sitagliptin and saxagliptin)

Does DPP-4 cause weight gain?

They do not cause hypoglycemia (low blood sugar) and generally do not cause any weight gain. They are usually prescribed as a secondary treatment in addition to or instead of metformin or sulfonylureas. DPP-4 inhibitors work by using the DPP-4 enzyme to inhibit the breakdown of GLP-1, a naturally occurring incretin hormone produced by the body, ...

Can DPP-4 be taken with insulin?

low blood sugar has been observed when a DPP-4 inhibitor is taken in combination with insulin or a sulfonylurea. The NIH article also has some contraindications for DPP-4 inhibitors: “Caution should be used in individuals with a history of pancreatitis; sitagliptin should be discontinued if pancreatitis is suspected.

What is the name of the drug that inhibits the enzyme dipeptidyl peptidase 4?

Sitagliptin ( Januvia), the first in a new class of antihyperglycemic agents, was approved in October 2006. It inhibits the enzyme dipeptidyl peptidase-4 (DPP-4), which causes the degradation of glucagon-like peptide-1 (GLP-1). The only other agent on the market that affects levels of GLP-1 is exen­ atide (Byetta).

What is the only other agent that affects levels of GLP-1?

The only other agent on the market that affects levels of GLP-1 is exen­ atide (Byetta). Exenatide is an injectable GLP-1 agonist, which mimics the action of naturally occurring GLP-1. Indications for sitagliptin include use in type 2 diabetes as monotherapy or in combination with metformin or thiazolidinediones. 3.

How much sitagliptin is excreted?

The majority of sitagliptin (79%) is excreted unchanged in the urine. For patients with moderate, severe, and end-stage renal disease, a dosage adjustment is required (see Table 2 ). Sitagliptin is available in 25-, 50-, and 100-mg tablets.

When did Novartis receive approval for Galvus?

In February 2007, Novartis received an approval letter from the FDA for vildagliptin (Galvus), another DPP-4 inhibitor. 29 One study of interest looked at vildagliptin in patients with type 2 diabetes who required insulin.

Is Liraglutide a human GLP?

Liraglutide is more like human GLP-1 than exenatide and is injected once daily. Disadvantages, compared to sitagliptin, include an injectable dosage form and gastrointestinal side effects. The most frequent side effects are nausea and diarrhea.

Does DPP-4 prevent weight gain?

The DPP-4 inhibitors offer the advantage of no weight gain. 7,11 It is unknown if DPP-4 inhibitors can prevent weight gain in the long term. DPP-4 inhibitors may be a treatment option for patients in whom metformin is contraindicated due to decreased renal function or intolerable gastrointestinal side effects.

Does GLP-1 affect beta cell function?

In type 2 diabetes, there is a progressive loss of beta-cell mass and function. GLP-1 increases endogenous insulin secretion, which supports the use of DPP-4 inhibitors early in the disease process. To date, there are few head-to-head trials comparing DPP-4 inhibitors to other antihyperglycemic agents.

What is DPP4 inhibitor?

DPP-4 inhibitors are a type of medication that people with type 2 diabetes can use to lower blood sugar levels.

How does GLP-1 help the body?

GLP-1 helps the body lower blood sugar levels by causing the pancreas to produce insulin after a meal. So, more GLP-1 means more insulin production and lower glucose levels. One way to increase levels of GLP-1 is by reducing levels of DPP-4.

Can DPP-4 be used with metformin?

DPP-4 inhibitors are used by people with type 2 diabetes. This medication is generally not the first drug prescribed to lower glucose levels. Some people add D PP-4s onto existing metformin therapy or take DPP-4s alone or with other drugs.

Is DPP4 a GLP-1 agonist?

DPP-4s have mild gastrointestinal side effects, including nausea, diarrhea, and stomach pain. DPP-4s are not as effective as GLP-1 agonist medications. While DPP-4s have fewer side effects, they provide less glucose control, weight loss, and overall treatment satisfaction.

Is DPP4 a pill?

Other drugs (such as sulfonylureas) have a higher risk of hypoglycemia, a major side effect of many glucose-lowering medications. DPP-4 is an oral drug (a pill) so there’s no need for injections.

Does DPP4 affect insulin production?

DPP-4 inhibitors lead to more GLP-1 that lasts longer in the bloodstream; this stimulates insulin production and decreases production of glucagon when glucose levels are high, lowering the body’s glucose levels.

Diagnosis

The “Incretin Effect”

Dipeptidyl Peptidase-4 Inhibitors

• Sitagliptin: The first DPP-4 inhibitor to enter the U.S. market, Sitagliptin (Januvia), was approved in October 2006 as adjunctive therapy to diet and exercise in the treatment of type 2 diabetes.13 It is a once-daily, highly selective, potent inhibitor of DPP-4 enzymes. Sitagliptin is eliminated primarily by the kidneys, with approximately 79% of ...

See more on uspharmacist.com

Advantages and Disadvantages to DPP-4 Inhibitor Use

Place in Therapy

Summary